Abstract
Depression is a common neuropsychiatric manifestation among Alzheimer’s disease (AD) patients. It may compromise everyday activities and lead to a faster cognitive decline as well as worse quality of life. The identification of promising biomarkers may therefore help to timely initiate and improve the treatment of preclinical and clinical states of AD, and to improve the long-term functional outcome. In this narrative review, we report studies that investigated biomarkers for AD-related depression. Genetic findings state AD-related depression as a rather complex, multifactorial trait with relevant environmental and inherited contributors. However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression. Regarding neuroimaging markers, the most promising findings reveal structural impairments in the cortico-subcortical networks that are related to affect regulation and reward / aversion control. Functional imaging studies reveal abnormalities in predominantly frontal and temporal regions. Furthermore, CSF based biomarkers are seen as potentially promising for the diagnostic process showing abnormalities in metabolic pathways that contribute to AD-related depression. However, there is a need for standardization of methodological issues and for replication of current evidence with larger cohorts and prospective studies.
Keywords: Alzheimer’s disease, depression, biomarkers, depression in Alzheimer´s Disease, neuroimaging, neurophysiology, genetics, serum biomarkers, BDNF.
Current Alzheimer Research
Title:Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review
Volume: 14 Issue: 4
Author(s): Sofia Wenzler, Christian Knochel, Ceylan Balaban, Dominik Kraft, Juliane Kopf, Gilberto S. Alves, David Prvulovic, Andre F. Carvalho and Viola Oertel-Knochel
Affiliation:
Keywords: Alzheimer’s disease, depression, biomarkers, depression in Alzheimer´s Disease, neuroimaging, neurophysiology, genetics, serum biomarkers, BDNF.
Abstract: Depression is a common neuropsychiatric manifestation among Alzheimer’s disease (AD) patients. It may compromise everyday activities and lead to a faster cognitive decline as well as worse quality of life. The identification of promising biomarkers may therefore help to timely initiate and improve the treatment of preclinical and clinical states of AD, and to improve the long-term functional outcome. In this narrative review, we report studies that investigated biomarkers for AD-related depression. Genetic findings state AD-related depression as a rather complex, multifactorial trait with relevant environmental and inherited contributors. However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression. Regarding neuroimaging markers, the most promising findings reveal structural impairments in the cortico-subcortical networks that are related to affect regulation and reward / aversion control. Functional imaging studies reveal abnormalities in predominantly frontal and temporal regions. Furthermore, CSF based biomarkers are seen as potentially promising for the diagnostic process showing abnormalities in metabolic pathways that contribute to AD-related depression. However, there is a need for standardization of methodological issues and for replication of current evidence with larger cohorts and prospective studies.
Export Options
About this article
Cite this article as:
Wenzler Sofia, Knochel Christian, Balaban Ceylan, Kraft Dominik, Kopf Juliane, Alves S. Gilberto, Prvulovic David, Carvalho F. Andre and Oertel-Knochel Viola, Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review, Current Alzheimer Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567205013666160603011256
DOI https://dx.doi.org/10.2174/1567205013666160603011256 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Denervation of the Olfactory Bulb Leads to Decreased Aβ Plaque Load in a Transgenic Mouse Model of Alzheimer’ s Disease
Current Alzheimer Research Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning
Current Pharmaceutical Design Aorta Remodeling Due to Stretch or Turbulent Flow/Low Wall Shear Stress: Distinctly Different Biological Phenomena?
Current Cardiology Reviews Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease
Current Topics in Medicinal Chemistry Subject Index to Volume 11
Protein & Peptide Letters Patent Selections:
Recent Patents on Regenerative Medicine From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research HIV Associated Neurodegenerative Disorders: A New Perspective on the Role of Lipid Rafts in Gp120-Mediated Neurotoxicity
Current HIV Research Blood Brain Barrier and Alzheimer’s Disease: Similarity and Dissimilarity of Molecular Alerts
Current Neuropharmacology Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress
Current Pharmacogenomics and Personalized Medicine Functional Imaging of Neurotransmission
Current Medical Imaging Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer’s Disease
Current Neurovascular Research Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Altered Amplitude of Low-frequency Fluctuations in Early and Late Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Risk Assessment During Longitudinal Progression of Cognition in Older Adults: A Community-based Bayesian Networks Model
Current Alzheimer Research